Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 4/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.56 |
| ▸ | GRM6 | O15303 | 3/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235483 | 1.00 | GRM8 (0.56) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL2235479 | 1.00 | GRM8 (0.56) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL4430629 | 1.00 | GRM8 (0.56) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL31652822 | 1.00 | GRM8 (0.56) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL12395373 | 0.87 | ALDH1A1 (0.56) | GRM8GRM4GRM6ACP3TP53 | |
| SCHEMBL27382091 | 0.83 | GRM8 (0.50) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL5861774 | 0.83 | ACP3 (0.58) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL21853750 | 0.83 | GRM8 (0.55) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL21853749 | 0.83 | GRM8 (0.55) | GRM8GRM4GRM6ACP3KMO | |
| SCHEMBL15229336 | 0.81 | ALDH1A1 (0.52) | GRM8GRM4GRM6ACP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-5378838-A | FOR USE IN HUMANS | MERCK & CO., INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994015924-A1 | CHOLECYSTOKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | GRM8 1001/4885GRM4 939/4885GRM6 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.